Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Increased vaccine sensitivity of an emerging SARS-CoV-2 variant

Joseph A. Lewnard, Vennis Hong, Jeniffer S. Kim, Sally F. Shaw, Bruno Lewin, Harpreet Takhar, Marc Lipsitch, Sara Y. Tartof
doi: https://doi.org/10.1101/2023.03.11.23287148
Joseph A. Lewnard
1Division of Epidemiology, School of Public Health, University of California, Berkeley, Berkeley, California 94720, United States
2Division of Infectious Diseases & Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, California 94720, United States
3Center for Computational Biology, College of Engineering, University of California, Berkeley, Berkeley, California 94720, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jLewnard@berkeley.edu Sara.Y.Tartof@kp.org
Vennis Hong
4Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California 91101, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeniffer S. Kim
4Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California 91101, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sally F. Shaw
4Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California 91101, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruno Lewin
4Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California 91101, United States
5Department of Clinical Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California 91101, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harpreet Takhar
4Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California 91101, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Lipsitch
6COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, 30329, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sara Y. Tartof
4Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California 91101, United States
7Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California 91101, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jLewnard@berkeley.edu Sara.Y.Tartof@kp.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Host immune responses are a key source of selective pressure driving pathogen evolution. Emergence of many SARS-CoV-2 lineages has been associated with improvements in their ability to evade population immunity resulting from both vaccination and infection. Here we show diverging trends of escape from vaccine-derived and infection-derived immunity for the emerging XBB/XBB.1.5 Omicron lineage. Among 31,739 patients tested in ambulatory settings in Southern California from December, 2022 to February, 2023, adjusted odds of prior receipt of 2, 3, 4, and ≥5 COVID-19 vaccine doses were 10% (95% confidence interval: 1-18%), 11% (3-19%), 13% (3-21%), and 25% (15-34%) lower, respectively, among cases infected with XBB/XBB.1.5 than among cases infected with other co-circulating lineages. Similarly, prior vaccination was associated with greater protection against progression to hospitalization among cases with XBB/XBB.1.5 than among non-XBB/XBB.1.5 cases (70% [30-87%] and 48% [7-71%], respectively, for recipients of ≥4 doses). In contrast, cases infected with XBB/XBB.1.5 had 17% (11-24%) and 40% (19-65%) higher adjusted odds of having experienced 1 and ≥2 prior documented infections, respectively, including with pre-Omicron variants. As immunity acquired from SARS-CoV-2 infection becomes increasingly widespread, fitness costs associated with enhanced vaccine sensitivity in XBB/XBB.1.5 may be offset by increased ability to evade infection-derived host responses.

Competing Interest Statement

JAL has received research grants paid directly to his institution and consulting honoraria unrelated to this study from Pfizer. SYT has received research grants paid directly to her institution unrelated to this study from Pfizer. The remaining authors disclose no competing interests.

Funding Statement

This work was funded by the US Centers for Disease Control and Prevention (CDC; grant 75D3-121C11520 to SYT). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. JAL was supported by grant R01-AI14812701A1 from the National Institute for Allergy and Infectious Diseases (US National Institutes of Health), which had no role in design or conduct of the study, or the decision to submit for publication.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Kaiser Permanente Southern California Institutional Review Board reviewed and provided ethical approval for the study.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

Individual-level testing and clinical outcomes data reported in this study are not publicly shared. Individuals wishing to access disaggregated data, including data reported in this study, should submit requests for access to the corresponding author (sara.y.tartof{at}kp.org). De-identified data (including, as applicable, participant data and relevant data dictionaries) will be shared upon approval of analysis proposals with signed data-access agreements in place.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted March 16, 2023.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Increased vaccine sensitivity of an emerging SARS-CoV-2 variant
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Increased vaccine sensitivity of an emerging SARS-CoV-2 variant
Joseph A. Lewnard, Vennis Hong, Jeniffer S. Kim, Sally F. Shaw, Bruno Lewin, Harpreet Takhar, Marc Lipsitch, Sara Y. Tartof
medRxiv 2023.03.11.23287148; doi: https://doi.org/10.1101/2023.03.11.23287148
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Increased vaccine sensitivity of an emerging SARS-CoV-2 variant
Joseph A. Lewnard, Vennis Hong, Jeniffer S. Kim, Sally F. Shaw, Bruno Lewin, Harpreet Takhar, Marc Lipsitch, Sara Y. Tartof
medRxiv 2023.03.11.23287148; doi: https://doi.org/10.1101/2023.03.11.23287148

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (228)
  • Allergy and Immunology (506)
  • Anesthesia (110)
  • Cardiovascular Medicine (1244)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (532)
  • Epidemiology (10027)
  • Forensic Medicine (5)
  • Gastroenterology (500)
  • Genetic and Genomic Medicine (2462)
  • Geriatric Medicine (238)
  • Health Economics (479)
  • Health Informatics (1645)
  • Health Policy (753)
  • Health Systems and Quality Improvement (636)
  • Hematology (250)
  • HIV/AIDS (535)
  • Infectious Diseases (except HIV/AIDS) (11871)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (253)
  • Medical Ethics (75)
  • Nephrology (268)
  • Neurology (2289)
  • Nursing (139)
  • Nutrition (352)
  • Obstetrics and Gynecology (454)
  • Occupational and Environmental Health (537)
  • Oncology (1248)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (325)
  • Pediatrics (733)
  • Pharmacology and Therapeutics (314)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2281)
  • Public and Global Health (4840)
  • Radiology and Imaging (838)
  • Rehabilitation Medicine and Physical Therapy (492)
  • Respiratory Medicine (651)
  • Rheumatology (286)
  • Sexual and Reproductive Health (240)
  • Sports Medicine (227)
  • Surgery (268)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)